Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

Peer Review reports

Original Submission
10 Aug 2011	Submitted	Original manuscript
27 Apr 2012	Reviewed	Reviewer Report - Primo Lara
11 Jun 2012	Reviewed	Reviewer Report - David Spigel
5 Jul 2012	Author responded	Author comments - Isamu Okamoto
Resubmission - Version 2
5 Jul 2012	Submitted	Manuscript version 2
Publishing
18 Jul 2012	Editorially accepted
1 Aug 2012	Article published	10.1186/1471-2407-12-327

Back to article page